VANCOUVER, British Columbia & OTTAWA, Ontario — Contextual Genomics, a leading cancer genomics company, and Eastern Ontario Regional Laboratory Association (EORLA), a nonprofit organization offering high quality, patient focused, hospital-based lab services in Eastern Ontario, announced that they have partnered to bring Contextual Genomics’ ctDNA cancer genomic testing to EORLA’s Champlain Local Health Integration Network (CLHIN) of Eastern Ontario, Canada.

Contextual Genomics has developed the FOLLOW IT® cancer panel, a multiplex, next-generation sequencing genomic assay evaluating the mutation status of tumour DNA in plasma, identifying the somatic mutations that have the greatest potential to impact treatment decisions. EORLA will offer FOLLOW IT to its network as a part of Contextual Genomics’ FOLLOW IT Canadian Early Access Program (CEAP). Indicated patients are expected to benefit from this new option by providing a less invasive alternative to tissue biopsy and by the addition of more convenient localized blood draw collection sites.

Contextual Genomics’ Canadian Early Access Program for FOLLOW IT plasma-based genomic cancer testing is underway in British Columbia and Ontario, offering a patient-pay test for individuals with metastatic lung, breast and colorectal cancer. The FOLLOW IT panel tests for actionable mutations, potentially leading to changes in disease management. All CEAP testing is performed in the Contextual Genomics’ clinically accredited laboratory in Vancouver and results are available in 5-10 business days.

“We are excited to be providing access to FOLLOW IT testing through the Contextual Genomics’ Canadian Early Access Program,” said Greg Dorion, Vice President, Operations of EORLA. “This offering is in line with EORLA’s purpose – to deliver patient-focused, consistent, high-quality and cost-effective hospital-based laboratory services to meet the needs of Eastern Ontarians.”

“The partnership with EORLA, in support of our FOLLOW IT Canadian Early Access Program, is important to Canadians in this region, allowing them better access to important health care. We look forward to working with EORLA to ensure that all cancer patients in their region that would benefit from FOLLOW IT testing will have access through their hospital Network,” Michael Ball, Contextual Genomics’ Chief Executive Officer, commented in a statement.

About Contextual Genomics (

Contextual Genomics develops cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are offered by our partner laboratories around the world with Contextual Genomics conducting cloud-based bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools allows Contextual Genomics to improve patient care through improved clinical trial enrollment and new treatment algorithms. Contextual Genomics is founded and managed by global leaders in cancer medicine and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.

About Contextual Genomics’ Products and CEAP:

Contextual Genomics has developed the FIND IT® and FOLLOW IT® cancer panels. Both panels are multiplex, next-generation sequencing genomic assays designed for rapid deployment into labs around the world. Both FIND IT and FOLLOW IT evaluate the mutation status of tumour DNA (FIND IT for solid tumours; FOLLOW IT for cell-free circulating tumour DNA in plasma) at 146 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions. QUALITY NEXUS® is a quality control system embedded into all FIND IT and FOLLOW IT assays and into Contextual Genomics’ cloud-based analysis engine. FIND IT and FOLLOW IT physician reports provide clear information on test interpretation and linkages to current therapeutic options. The FOLLOW IT Canadian Early Access Program is a program being run by Contextual Genomics in British Columbia and Ontario to provide patient-pay access to FOLLOW IT for patients with metastatic breast, lung and GI cancers.

About EORLA:

The Eastern Ontario Regional Laboratory Association (EORLA) is a member-owned, non-profit organization encompassing the operation of 19 licensed, acute-care, hospital-based clinical laboratories that service clinical programs across the Champlain Local Health Integration Network (CLHIN) of Eastern Ontario. A leading, innovative model of integrated laboratory practices in the province, the purpose of EORLA is to deliver patient-focused, consistent, high-quality and cost-effective hospital-based laboratory services to meet the needs of the region’s patients.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


Recent Resources


February 17, 2021

How 3 organizations are tackling disparities in cancer care

Before COVID-19 lockdowns halted travel, I attended a community cancer conference in Washington D.C. last year. I had an interesting conversation with a community practice leader, Jessica, about how socioeconomic factors have a big impact on clinical outcomes. In the last few months, I have been researching value-based care innovations in cancer care. I was encouraged to find multiple examples of value-based care initiatives that also focus on reducing disparities. How are they approaching challenges of inequity in cancer care? Here are three initiatives with innovative approaches.

In the News

February 4, 2021

Pilot of new cancer test in Canada shows promise as faster alternative to conventional biopsies

The COVID-19 pandemic has delayed thousands of surgical procedures across the country, including tissue biopsies needed for cancer diagnosis. But it’s also pushing demand for alternatives that allow patients to be tested for signs of tumours without even needing to enter a hospital. As part of a new pilot called Project ACTT, more than 800 Canadian cancer patients have been tested through liquid biopsies, which involve taking a blood sample and looking for signs of tumour DNA. That federally funded project, a partnership led by Vancouver-based Canexia Health, offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.


February 1, 2021

Cancer is going undiagnosed during COVID-19. Here’s what we know so far.

Last spring’s wave of COVID-19 delays to cancer care, and a prolonged pandemic, have resulted in disturbing trends for patients that, while not unexpected, are now being quantified. Dozens of major cancer centers and organizations across the US, including the National Comprehensive Cancer Network and American Cancer Society, issued an urgent call to action: cancer screening and treatment during COVID-19 must resume at full speed and at full scale.